Dennis O'Neill

President at BIOMEDICAN
On the record
Represented by:
Recent Quotes
Sign up to view all
  • Biosynthesis of rare cannabinoids is one of the fastest-growing markets in the world today, and BIOMEDICAN is uniquely positioned with what we believe are the best IP and results in the space. Our IP has delivered the highest yields in the market, and we are using 60-70% less sugar [the main ingredient in biosynthesis] than our competitors based on our intel. This is just the beginning; we will have several additional cannabinoid strains ready for the market in the coming months.

    6 December 2020
Sign up to view all